Remove Leveraging Remove Securities and Exchange Commission (SEC) Remove Whitepaper
article thumbnail

Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript

The Motley Fool

The press release is available on our website at sarepta.com, and our 10-Q was filed with the Securities and Exchange Commission this afternoon. And on top of this, the patients must also secure access to ELEVIDYS in this very short time window. Uy Ear -- Mizuho Securities -- Analyst Hey, guys. Operator Thank you.